Related Experiment Video
Updated: Feb 28, 2026
Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans
Published on: August 15, 2020
Drug repurposing for aging research using model organisms
Matthias Ziehm1,2, Satwant Kaur1, Dobril K Ivanov1
1European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), The Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
Abstract:
Many increasingly prevalent diseases share a common risk factor: age. However, little is known about pharmaceutical interventions against aging, despite many genes and pathways shown to be important in the aging process and numerous studies demonstrating that genetic interventions can lead to a healthier aging phenotype. An important challenge is to assess the potential to repurpose existing drugs for initial testing on model organisms, where such experiments are possible. To this end, we present a new approach to rank drug-like compounds with known mammalian targets according to their likelihood to modulate aging in the invertebrates Caenorhabditis elegans and Drosophila. Our approach combines information on genetic effects on aging, orthology relationships and sequence conservation, 3D protein structures, drug binding and bioavailability. Overall, we rank 743 different drug-like compounds for their likelihood to modulate aging. We provide various lines of evidence for the successful enrichment of our ranking for compounds modulating aging, despite sparse public data suitable for validation. The top ranked compounds are thus prime candidates for in vivo testing of their effects on lifespan in C. elegans or Drosophila. As such, these compounds are promising as research tools and ultimately a step towards identifying drugs for a healthier human aging.
Insights
Researchers developed a new method to identify existing drugs that may slow aging. This approach ranks compounds for their potential to impact aging in model organisms, aiding the search for healthier human aging strategies.
Area of Science:
- Gerontology and pharmaceutical science
- Computational biology and drug discovery
Background:
- Aging is a major risk factor for prevalent diseases, yet pharmaceutical interventions targeting aging remain underexplored.
- Genetic studies reveal key aging pathways and demonstrate that genetic interventions can promote healthier aging phenotypes.
Purpose of the Study:
- To develop and validate a computational approach for ranking existing drug-like compounds based on their potential to modulate aging.
- To identify promising compounds for experimental testing in model organisms (Caenorhabditis elegans and Drosophila) to assess their effects on lifespan and aging.
Main Methods:
- Integrated diverse data sources including genetic effects on aging, gene orthology, sequence conservation, protein structures, and drug properties (binding, bioavailability).
- Developed a novel ranking system to predict the likelihood of drug-like compounds modulating aging processes.
- Applied the ranking approach to a library of 743 drug-like compounds with known mammalian targets.
Main Results:
- Successfully ranked 743 drug-like compounds based on their predicted impact on aging.
- Demonstrated enrichment of the ranking with compounds known to affect aging, despite limited validation data.
- Identified top-ranked compounds as prime candidates for in vivo lifespan studies in C. elegans and Drosophila.
Conclusions:
- The developed computational approach effectively prioritizes drug candidates for aging research.
- Top-ranked compounds represent valuable tools for investigating aging mechanisms and developing interventions for healthier human aging.
More Related Videos
10:19Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
Published on: August 22, 2014
08:20Robust Tissue Fabrication for Long-Term Culture of iPSC-Derived Brain Organoids for Aging Research
Published on: May 12, 2023